Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock

Spyre Therapeutics CFO Scott Burrows sold $2.26 million worth of stock in a series of transactions on September 30 and October 1, 2026. On September 30, Burrows disposed of 17,500 shares at a weighted average price of $89.89 per share, totaling approximately $1.57 million. Two days later, on October 1, he sold an additional 7,500 shares at varying prices, accumulating about $688,755 in sales.

These sell-offs were executed under a pre-existing Rule 10b5-1 trading plan. Concurrently, Burrows exercised stock options to acquire 17,500 shares at $14.50 per share, amounting to $253,750. By the end of the period, Burrows owned 79,762 shares of Spyre Therapeutics, including 33,738 Restricted Stock Units (RSUs) that vest on September 1, 2027, contingent upon continued employment.

He also holds 312,357 derivative securities in the form of stock options. Analysts have noted the stock's volatility, with a beta of 3, and suggest it may be overvalued based on current market conditions. Recent clinical trial results and analyst ratings from firms like Guggenheim, Stifel, Baird, and JPMorgan have provided mixed assessments of the company's prospects.